GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Taysha Gene Therapies Inc (NAS:TSHA) » Definitions » EPS (Basic)

TSHA (Taysha Gene Therapies) EPS (Basic) : $-0.34 (TTM As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Taysha Gene Therapies EPS (Basic)?

Taysha Gene Therapies's basic earnings per share (Basic EPS) for the three months ended in Mar. 2025 was $-0.08. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2025 was $-0.34.

Taysha Gene Therapies's EPS (Diluted) for the three months ended in Mar. 2025 was $-0.08. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was $-0.34.

Taysha Gene Therapies's EPS without NRI for the three months ended in Mar. 2025 was $-0.08. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2025 was -0.32.

During the past 3 years, the average EPS without NRI Growth Rate was 58.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 6 years, Taysha Gene Therapies's highest 3-Year average EPS without NRI Growth Rate was 58.10% per year. The lowest was 42.70% per year. And the median was 50.40% per year.


Taysha Gene Therapies EPS (Basic) Historical Data

The historical data trend for Taysha Gene Therapies's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Taysha Gene Therapies EPS (Basic) Chart

Taysha Gene Therapies Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EPS (Basic)
Get a 7-Day Free Trial -3.40 -4.64 -3.78 -0.96 -0.36

Taysha Gene Therapies Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.10 -0.09 -0.10 -0.07 -0.08

Taysha Gene Therapies EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Taysha Gene Therapies's Basic EPS for the fiscal year that ended in Dec. 2024 is calculated as

Basic EPS (A: Dec. 2024 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-89.298-0)/250.134
=-0.36

Taysha Gene Therapies's Basic EPS for the quarter that ended in Mar. 2025 is calculated as

Basic EPS (Q: Mar. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-21.529-0)/269.306
=-0.08

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Taysha Gene Therapies  (NAS:TSHA) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Taysha Gene Therapies EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Taysha Gene Therapies's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.


Taysha Gene Therapies Business Description

Traded in Other Exchanges
N/A
Address
3000 Pegasus Park Drive, Suite 1430, Dallas, TX, USA, 75247
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
Executives
Paul B Manning director, 10 percent owner 200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Alison S Long director KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVENUE, LEXINGTON MA 02421
Kamran Alam officer: Chief Financial Officer 350 FIFTH AVENUE, SUITE 7530, NEW YORK NY 10118
Sean P. Nolan director C/O INTERMUNE, INC., 3280 BAYSHORE BLVD., BRISBANE CA 94005
Phillip B. Donenberg director C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 200, BANNOCKBURN IL 60015
Stalfort John A Iii director C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902
Session R.a. Ii 10 percent owner C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 200, BANNOCKBURN IL 60015
Sukumar Nagendran director C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 160, BANNOCKBURN IL 60015
Astellas Pharma Inc. 10 percent owner 2-5-1, NIHONBASHI-HONCHO, CHUO-KU, TOKYO M0 103-8411
Audentes Therapeutics, Inc. 10 percent owner 600 CALIFORNIA ST., 17TH FLOOR, SAN FRANCISCO CA 94108
Suyash Prasad officer: CMO and Head of R&D C/O AUDENTES THERAPEUTICS, INC., 101 MONTGOMERY ST., SUITE 2650, SAN FRANCISCO CA 94104
Laura Sepp-lorenzino director C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139
Kathleen Reape director C/O TAYSHA GENE THERAPIES, INC., 2280 INWOOD ROAD, DALLAS TX 75235